Healthcare of Ontario Pension Plan Trust Fund Increases Position in Quest Diagnostics Incorporated $DGX

Healthcare of Ontario Pension Plan Trust Fund increased its holdings in shares of Quest Diagnostics Incorporated (NYSE:DGX) by 1.5% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 170,912 shares of the medical research company’s stock after acquiring an additional 2,515 shares during the quarter. Healthcare of Ontario Pension Plan Trust Fund owned approximately 0.15% of Quest Diagnostics worth $33,495,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Brighton Jones LLC bought a new stake in shares of Quest Diagnostics during the 4th quarter worth $323,000. Cresset Asset Management LLC grew its position in Quest Diagnostics by 4.6% during the second quarter. Cresset Asset Management LLC now owns 4,003 shares of the medical research company’s stock valued at $719,000 after buying an additional 176 shares during the period. Gabelli Funds LLC bought a new position in Quest Diagnostics during the second quarter valued at about $287,000. Bank of Nova Scotia increased its holdings in Quest Diagnostics by 7.2% during the second quarter. Bank of Nova Scotia now owns 14,339 shares of the medical research company’s stock worth $2,576,000 after buying an additional 962 shares during the last quarter. Finally, Daiwa Securities Group Inc. raised its position in Quest Diagnostics by 17.1% in the second quarter. Daiwa Securities Group Inc. now owns 18,599 shares of the medical research company’s stock worth $3,341,000 after acquiring an additional 2,718 shares during the period. Hedge funds and other institutional investors own 88.06% of the company’s stock.

Quest Diagnostics Stock Performance

NYSE:DGX opened at $228.05 on Monday. The business’s fifty day moving average is $203.23 and its 200 day moving average is $197.76. The firm has a market cap of $25.17 billion, a price-to-earnings ratio of 24.21, a PEG ratio of 2.61 and a beta of 0.58. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.46 and a current ratio of 1.59. Quest Diagnostics Incorporated has a 52-week low of $165.78 and a 52-week high of $237.78.

Quest Diagnostics (NYSE:DGX) last issued its earnings results on Thursday, July 23rd. The medical research company reported $3.12 EPS for the quarter, topping the consensus estimate of $2.82 by $0.30. The business had revenue of $3.04 billion during the quarter, compared to the consensus estimate of $2.97 billion. Quest Diagnostics had a return on equity of 16.01% and a net margin of 9.18%.The firm’s revenue was up 10.2% compared to the same quarter last year. During the same quarter last year, the company earned $2.62 EPS. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. Research analysts predict that Quest Diagnostics Incorporated will post 11.17 EPS for the current year.

Quest Diagnostics Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, July 22nd. Stockholders of record on Wednesday, July 8th were issued a $0.86 dividend. This represents a $3.44 dividend on an annualized basis and a dividend yield of 1.5%. The ex-dividend date of this dividend was Wednesday, July 8th. Quest Diagnostics’s dividend payout ratio is presently 36.52%.

Insider Buying and Selling

In related news, CEO J. E. Davis sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $194.14, for a total transaction of $1,941,400.00. Following the sale, the chief executive officer owned 132,423 shares of the company’s stock, valued at approximately $25,708,601.22. This represents a 7.02% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Karthik Kuppusamy sold 8,147 shares of the stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $200.00, for a total transaction of $1,629,400.00. Following the completion of the sale, the senior vice president owned 13,510 shares in the company, valued at $2,702,000. This represents a 37.62% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.88% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on DGX shares. Robert W. Baird boosted their target price on shares of Quest Diagnostics from $236.00 to $255.00 and gave the company a “neutral” rating in a research note on Friday. UBS Group restated a “neutral” rating and set a $232.00 price target on shares of Quest Diagnostics in a research note on Friday. Weiss Ratings raised shares of Quest Diagnostics from a “buy (b)” rating to a “buy (b+)” rating in a report on Thursday, July 9th. Truist Financial upped their price objective on Quest Diagnostics from $225.00 to $250.00 and gave the company a “hold” rating in a research note on Friday. Finally, Evercore set a $225.00 price objective on Quest Diagnostics in a report on Tuesday, April 21st. Six investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, Quest Diagnostics presently has a consensus rating of “Moderate Buy” and a consensus target price of $231.73.

More Quest Diagnostics News

Here are the key news stories impacting Quest Diagnostics this week:

• Positive Sentiment: Quest Diagnostics posted Q2 results that beat Wall Street expectations on both revenue and earnings, helped by stronger demand for routine diagnostic and preventive testing. The company also raised its full-year 2026 outlook, which investors are reading as evidence that growth is holding up well. Article: Quest Diagnostics Reports Second Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026
• Positive Sentiment: Mizuho raised its price target on DGX to $260 and kept an outperform rating, signaling confidence that the company can still outperform from here. Article: Quest Diagnostics price target raised by Mizuho
• Positive Sentiment: Truist also lifted its target to $250, while Robert W. Baird increased its target to $255, reflecting continued analyst optimism after the earnings beat and raised guidance. Article: Quest Diagnostics price target raised by Truist Financial Corporation
• Neutral Sentiment: Several market commentary pieces highlighted DGX as a momentum stock and noted the shares recently reached a 52-week high. That supports bullish sentiment, but these articles are mostly follow-up coverage rather than a new fundamental catalyst. Article: Are You Looking for a Top Momentum Pick? Why Quest Diagnostics (DGX) Is a Great Choice

Quest Diagnostics Profile

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.